ReviewNeurosurgical focus2014
Bevacizumab for glioblastoma: current indications, surgical implications, and future directions.
Review in Neurosurgical focus, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of neuropathology in the management of progressive glioblastoma in adults.Journal of neuro-oncology · 2022Pooled it
- Hemorrhagic and ischemic risks of anti-VEGF therapies in glioblastoma.Cancer gene therapy · 2025Review
- Practical immunomodulatory landscape of glioblastoma multiforme (GBM) therapy.Journal of the Egyptian National Cancer Institute · 2024Review
- Engineered smart materials for RNA based molecular therapy to treat Glioblastoma.Bioactive materials · 2024Article
- Bispecific antibody shuttles targeting CD98hc mediate efficient and long-lived brain delivery of IgGs.Cell chemical biology · 2024Article
- Fibronectin Type III Domain Containing 3B as a Potential Prognostic and Therapeutic Biomarker for Glioblastoma.Biomedicines · 2023Article
- 4-Methylumbelliferone enhances the effects of chemotherapy on both temozolomide-sensitive and resistant glioblastoma cells.Scientific reports · 2023Article
- Glioma stem cell signature predicts the prognosis and the response to tumor treating fields treatment.CNS neuroscience & therapeutics · 2022Article
- Review
- ZNF655 accelerates progression of pancreatic cancer by promoting the binding of E2F1 and CDK1.Oncogenesis · 2022Article
- Emerging therapies for glioblastoma: current state and future directions.Journal of experimental & clinical cancer research : CR · 2022Review
- P4HA1 Regulates CD31Frontiers in oncology · 2022Article
- The adaptive transition of glioblastoma stem cells and its implications on treatments.Signal transduction and targeted therapy · 2021Review
- Against the Resilience of High-Grade Gliomas: The Immunotherapeutic Approach (Part I).Brain sciences · 2021Review
- Strategies to better treat glioblastoma: antiangiogenic agents and endothelial cell targeting agents.Future medicinal chemistry · 2021Review
- Article
- Aptamer-Driven Toxin Gene Delivery in U87 Model Glioblastoma Cells.Frontiers in pharmacology · 2021Article
- Nanodelivery Systems Targeting Epidermal Growth Factor Receptors for Glioma Management.Pharmaceutics · 2020Review
- Article
- Developing effective combination therapy for pancreatic cancer: An overview.Pharmacological research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Initial enthusiasm after promising Phase II trials for treating recurrent glioblastomas with the antiangiogenic drug bevacizumab—a neutralizing antibody targeting vascular endothelial growth factor—was tempered by recent Phase III trials showing no efficacy for treating newly diagnosed glioblastomas. As a result, there is uncertainty about the appropriate indications for the use of bevacizumab in glioblastoma treatment. There are also concerns about the effects of bevacizumab on wound healing that neurosurgeons must be aware of. In addition, biochemical evidence suggests a percentage of tumors treated with bevacizumab for an extended period of time will undergo transformation into a more biologically aggressive and invasive phenotype with a particularly poor prognosis. Despite these concerns, there remain numerous examples of radiological and clinical improvement after bevacizumab treatment, particularly in patients with recurrent glioblastoma with limited therapeutic options. In this paper, the authors review clinical results with bevacizumab for glioblastoma treatment to date, ongoing trials designed to address unanswered questions, current clinical indications based on existing data, neurosurgical implications of bevacizumab use in patients with glioblastoma, the current scientific understanding of the tumor response to short- and long-term bevacizumab treatment, and future studies that will need to be undertaken to enable this treatment to fulfill its therapeutic promise for glioblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.